Extensive pharmacokinetic profiling of possible oxaborole compounds led to the selection of SCYX-1608210 and SCYX‑1330682, which demonstrated cure in the stage 2 mouse model of HAT, as a backup for acoziborole (SCYX-7158) in case of need. Given the current success of other projects for HAT, further development was put on hold in 2013 and will only recommence should problems be encountered with acoziborole (SCYX-7158) in clinical development.

Project updates

2019

DNDi  continues to provide support and advice to researchers working on discovery of new candidates for HAT and maintains two back-up candidates from the oxaborole class to ensure future development options, if needed.

2018

DNDi continues to provide support and advice to researchers working on discovery of new candidates for HAT and maintains two back-up candidates from the oxaborole class to ensure future development options, if needed.